![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00555139 |
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
Condition | Intervention | Phase |
---|---|---|
Social Anxiety Disorder |
Drug: GSK561679 Drug: GW876008 Drug: alprazolam |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Double-Blind, Randomized, Placebo and Alprazolam-Controlled Three-Period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-Like fRMI Activity of GW876008 and GSK561679 After Single-Dose Administration in Subjects With Social Anxiety Disorder (SAD) |
Enrollment: | 35 |
Study Start Date: | March 2007 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Spain | |
GSK Investigational Site | |
Barcelona, Spain, 08025 | |
GSK Investigational Site | |
Sabadell (Barcelona), Spain, 08208 | |
GSK Investigational Site | |
Terrassa - Barcelona, Spain, 08227 | |
GSK Investigational Site | |
Barcellona, Spain, 08025 | |
GSK Investigational Site | |
Hospitalet de Llobregat, Spain, 08907 | |
GSK Investigational Site | |
Mataro (Barcelona), Spain | |
GSK Investigational Site | |
Barcelona, Spain, 08035 | |
GSK Investigational Site | |
Barcelona, Spain | |
GSK Investigational Site | |
Barcelona, Spain, E-08003 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | CRH108571 |
Study First Received: | November 5, 2007 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00555139 |
Health Authority: | Spain: Spanish Agency of Medicines |
CRF-1 antagonists, depression, anxiety, fMRI |
Alprazolam Depression Anxiety Disorders |
Mental Disorders Phobic Disorders Depressive Disorder |
Neurotransmitter Agents Disease Tranquilizing Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Pharmacologic Actions Pathologic Processes Therapeutic Uses Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Central Nervous System Agents |